22:36 , Apr 4, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: March 2018

New Therapeutic Targets and Biomarkers: March 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during March 2018. Therapeutic targets are defined as any protein, gene or other...
23:06 , Mar 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cervical cancer Cell culture studies suggest inhibiting EDC4 could help treat cervical cancer. In HeLa cells, siRNA targeting EDC4 plus the generic chemotherapy mitomycin decreased survival compared with mitomycin alone. Next steps could include...
19:35 , Dec 5, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Spinal cord injury (SCI) Mouse studies suggest MaR1 could help treat acute spinal cord injury (SCI). In a mouse model of SCI, daily IV injection of MaR1 for seven days increased locomotor recovery, myelin...
07:00 , Sep 4, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Depression Serotonin (5-HT7) receptor In vitro and mouse studies suggest selectively blocking the 5-HT7 receptor could enable rapid treatment of depression. Serotonin reuptake inhibitors are...
07:00 , May 22, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) CREB-regulated transcription coactivator 1 (CRTC1; TORC1) Human and mouse studies suggest agonizing CRTC1 could help treat AD. In patients with intermediate and...
07:00 , Aug 1, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Mucopolysaccharidosis N-sulfoglucosamine sulfohydrolase (SGSH; HNS) Animal studies suggest SGSH gene therapy could help treat mucopolysaccharidosis IIIA (MPS IIIA). In mouse...
07:00 , Jul 25, 2013 |  BC Innovations  |  Cover Story

MPS IIIA: gene therapy for brain and body

Less than a year after reporting preclinical proof of concept for a systemically delivered mucopolysaccharidosis IIIA gene therapy, researchers at the Autonomous University of Barcelona have shown that intracerebral delivery can substantially improve efficacy in...
07:00 , Jul 28, 2011 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Aminocyclitol phytoceramides as vaccine adjuvants Mouse and cell culture studies identified aminocyclitol phytoceramide compounds that could be useful as vaccine adjuvants. In invariant NK T...
08:00 , Mar 10, 2011 |  BC Innovations  |  Targets & Mechanisms

De-amping the HER2 environment

A team from the University of Pennsylvania School of Medicine and another from the Massachusetts General Hospital Cancer Center and Cyclacel Pharmaceuticals Inc. have independently identified strategies to improve clinical outcomes for patients with HER2-positive...
08:00 , Feb 17, 2011 |  BC Innovations  |  Targets & Mechanisms

Protecting against latent TB

A team of EU and U.S. researchers has created a subunit vaccine based on three Mycobacterium tuberculosis antigens and shown that it protects healthy mice from tuberculosis and prevents reactivation of disease in mouse models...